Earnings Call Summary | MICROBIX BIOSYSTEMS(MBXBF.US) Q2 2024 Earnings Conference
Earnings Call Summary | MICROBIX BIOSYSTEMS(MBXBF.US) Q2 2024 Earnings Conference
The following is a summary of the Microbix Biosystems Inc. (MBXBF) Q2 2024 Earnings Call Transcript:
以下是Microbix Biosystems Inc.（MBXBF）2024年第二季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Microbix Biosystems Inc. reported Q2 revenues of $5.6 million, a 34% increase year-over-year, largely driven by an increase in product sales.
The company observed gross margins around 52-53% for the quarter, reflecting a net income of around $400,000 and a net margin of 7%.
Notable growth was seen in the test ingredients business, with over $4 million in sales for the quarter.
The company maintains a strong order backlog of over $9 million and a robust cash position of over $12 million, despite capital equipment purchases and share buy-back programs.
Microbix Biosystems Inc.報告稱，第二季度收入爲560萬美元，同比增長34％，這主要是由產品銷售增長推動的。
該公司本季度毛利率約爲52-53％，淨收入約爲40萬美元，淨利潤率爲7％。
測試原料業務顯著增長，本季度銷售額超過400萬美元。
儘管有資本設備購買和股票回購計劃，但該公司仍保持着超過900萬美元的強勁訂單積壓和超過1200萬美元的強勁現金狀況。
Business Progress:
業務進展：
Significant growth has been noted across all categories, with particular traction in the test ingredients and CAPS business.
Microbix is dedicated to domain innovations, developing novel formats for QAPs products, and broadening its expertise into oncology.
The company has strategically utilized government grant funding and interest-free loans to increase productivity and market performance.
Continued growth of the Kinlytic CDMO engagement through Microbix's relationship with Sequel.
Strong expectation of a 40% growth rate in the QAPs business this year and a solid order backlog indicates promising future performance.
所有類別均實現了顯著增長，測試原料和CAPS業務尤其受歡迎。
Microbix致力於領域創新，爲QAPs產品開發新格式，並將其專業知識擴展到腫瘤學領域。
該公司戰略性地利用了政府撥款和無息貸款來提高生產率和市場表現。
通過Microbix與Sequel的關係，Kinlytic CDMO的參與度持續增長。
對今年QAPs業務增長40％的強烈預期以及穩健的訂單積壓表明未來表現樂觀。
More details: MICROBIX BIOSYSTEMS IR
更多詳情： 微盒生物系統 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。